Boston Scientific Corporation

1526 articles with Boston Scientific Corporation

• Boston Scientific Launches Vercise Genus™ DBS System In Europe

  9/9/2020

  Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in Europe

• CMS Grants Additional Reimbursement For The Eluvia™ Drug-Eluting Vascular Stent System

  9/3/2020

  Boston Scientific announced that the U.S. Centers for Medicare and Medicaid Services granted a New Technology Add-on Payment for the Eluvia™ Drug-Eluting Vascular Stent System as part of the 2021 Inpatient Prospective Payment System.

• Boston Scientific Announces September 2020 Conference Schedule

  8/26/2020

  Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On September 9, 2020 , Mike Mahoney , chairman and chief executive officer, and Susie

• BioTelemetry, Inc. Announces Sales Agent Agreement with Boston Scientific Corporation

  7/30/2020

  BioTelemetry, Inc., the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced a sales agent agreement with Boston Scientific, a global medical technology leader.

• Boston Scientific Announces Results For Second Quarter 2020

  7/29/2020

  Boston Scientific Corporation generated sales of $2.003 billion during the second quarter of 2020.

• Boston Scientific Receives FDA Approval for Next-Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

  7/21/2020

  Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.

• Michael Enxing joins PainTEQ Board of Directors

  7/1/2020

  PainTEQ, a leading medical device innovator, announced the appointment of Michael Enxing, Chief Commercial Officer of Boston Scientific Corporation, Neuromodulation Division.

• Boston Scientific Announces Conference Call Discussing Second Quarter 2020 Financial Results

  6/30/2020

  Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2020 on Wednesday, July 29, 2020 at 8:00 a.m. EDT.

• Boston Scientific Receives FDA 510(k) Clearance for the LUX-Dx™ Insertable Cardiac Monitor System

  6/29/2020

  Boston Scientific has received U.S. Food and Drug Administration 510 clearance for the LUX-Dx™ Insertable Cardiac Monitor System, a new, long-term diagnostic device implanted in patients to detect arrhythmias associated with conditions such as atrial fibrillation, cryptogenic stroke and syncope.

• Boston Scientific Receives Medicare Transitional Pass-Through Payment for the EXALT™ Model D Single-Use Duodenoscope

  6/8/2020

  Boston Scientific announced that the Centers for Medicare & Medicaid Services has approved its application for a transitional pass-through payment category to describe single-use endoscopes, including the EXALT™ Model D Single-Use Duodenoscope, under the Medicare hospital outpatient prospective payment system.

• Boston Scientific Launches DIRECTSENSE™ Technology

  6/1/2020

  Tool provides electrophysiologists with first-ever local measurement and visualization of tissue response to radiofrequency ablation

• Boston Scientific Completes Approximately $2.0 Billion Aggregate Offerings of Common Stock and Mandatory Convertible Preferred Stock

  5/28/2020

  Boston Scientific Corporation completed the concurrent offerings of 29,382,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 3,832,500 additional shares of common stock

• Boston Scientific to Participate in Jefferies 2020 Healthcare Conference

  5/26/2020

   Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Jefferies 2020 Virtual Healthcare Conference on June 2 . Joe Fitzgerald , executive vice president and president, Rhyth

• Boston Scientific Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock

  5/21/2020

  Boston Scientific Corporation (NYSE: BSX) announced the pricing of concurrent offerings of 25,550,000 shares of its common stock ("Common Stock") at a price to the public of $34.25 per share and 8,750,000 shares of its 5.50% Mandatory Convertible Preferred Stock, Series A

• Boston Scientific Announces Offerings of Common Stock and Mandatory Convertible Preferred Stock

  5/20/2020

  Boston Scientific Corporation (NYSE: BSX) announced that it has commenced concurrent offerings of $750.0 million of shares of its common stock ("Common Stock") and $750.0 million of shares of its Series A Mandatory Convertible Preferred Stock

• Boston Scientific Completes $1.7 Billion Offering of Senior Notes

  5/18/2020

  Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.7 billion aggregate principal amount of its senior notes

• Boston Scientific Prices $1.7 Billion of Senior Notes

  5/14/2020

  Boston Scientific Corporation announced the pricing of a public offering of $1.7 billion aggregate principal amount of its senior notes under the company's shelf registration statement.

• PINNACLE FLX Study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device Presented as Late-Breaking Clinical Trial at HRS 2020 SCIENCE

  5/8/2020

  Trial meets primary safety and efficacy endpoints with low complication rates, 100% effective closure with next-generation stroke risk reduction technology for patients with non-valvular atrial fibrillation

• Late-Breaking Clinical Trial Data Underscore Safety And Efficacy Of Boston Scientific S-ICD System

  5/8/2020

  Outcomes presented at HRS 2020 SCIENCE demonstrate device benefits for patients at risk of sudden cardiac death

• Boston Scientific Announces May 2020 Virtual Conference Schedule

  5/6/2020

  Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming virtual investor conferences. On May 13, 2020 , Dan Brennan , executive vice president and chief financial officer,